Arcutis Biotherapeutics (ARQT) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Commercial strategy and growth outlook

• Focus on expanding ZORYVE across psoriasis, atopic dermatitis, and seborrheic dermatitis, with commercial investments and marketing to drive growth.

• Label expansions targeted for nail psoriasis, scarring alopecia, vitiligo, and hidradenitis suppurativa, with collaborative research underway.

• Achieved cash flow break-even in Q4 and expect to remain sustainably so through 2026.

• Peak sales forecast of $2.6B–$3.5B, assuming 15–20% market share, with $300M–$500M from new indications.

• Expansion of sales force to 160+ reps and creation of a targeted PCP/pediatric team to deepen market penetration.

Shifts in dermatology practice and guidelines

• Growing movement among dermatologists to reduce reliance on topical corticosteroids due to systemic effects from long-term use.

• New non-steroidal options like ZORYVE are enabling lifetime management of inflammatory skin diseases without steroids.

• Guidelines, especially for atopic dermatitis in young children, are evolving to reflect these changes.

• Strong push for chronic therapy options that parents can use daily without steroid-related concerns.

Pediatric and new indication opportunities

• ZORYVE approved for atopic dermatitis down to age 2, with strong efficacy and safety data in 3–24 month-olds.

• Nearly 1 million pediatric patients in the 3–24 month range represent a significant growth segment.

• Studies initiated for vitiligo and hidradenitis suppurativa, with go/no-go decisions expected in Q4 (vitiligo) and Q1 next year (HS).

• Incremental $300M–$500M in peak sales from these new indications is risk-adjusted.